News

Press Releases

For more information about the history of the company and our technology, click here.

 
Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
– Enrollment continues with multiple trial sites now opening across the U.S. – BOSTON, Mass., and LOUISVILLE, Ky., July 22,...  READ MORE
FDA Approves Talaris Therapeutics’ IND for its Allogeneic Cell Therapy FCR001 to be Evaluated in Patients with a Severe Form of Scleroderma
BOSTON, Mass., and LOUISVILLE, Ky., July 8, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Update on Talaris’ Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress
– Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ – BOSTON, Mass., May 29, 2020...  READ MORE
Talaris Therapeutics to Present at American Society of Hematology (ASH) Annual Meeting
BOSTON, Mass., and LOUISVILLE, Ky., Dec. 6, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Talaris Therapeutics Presents Data Supporting Potential of FCR001 to Prevent Recurrence of Kidney-Related Autoimmune Disease in Kidney Transplant Recipients
BOSTON, Mass., and LOUISVILLE, Ky., Nov. 7, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Pivotal trial to evaluate the safety and efficacy of novel, investigational cell therapy intended to durably free living donor kidney...  READ MORE
Talaris Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
BOSTON, Mass., and LOUISVILLE, Ky., Sept. 26, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Talaris Therapeutics Wins 2019 “Big Idea” Xconomy Award
BOSTON, Mass., and LOUISVILLE, Ky., September 18, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Talaris Therapeutics Presents Data Demonstrating Improved Quality of Life for Patients Treated with FCR001
BOSTON, Mass., and LOUISVILLE, Ky., June 2, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies in...  READ MORE
Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients
FCR001 established durable immune tolerance in 70% of patients Results support initiation of Phase 3 registration study later this year...  READ MORE